These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12141888)

  • 1. Direct medical cost of managing deep vein thrombosis according to the occurrence of complications.
    O'Brien JA; Caro JJ
    Pharmacoeconomics; 2002; 20(9):603-15. PubMed ID: 12141888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin.
    Spyropoulos AC; Hurley JS; Ciesla GN; de Lissovoy G
    Chest; 2002 Jul; 122(1):108-14. PubMed ID: 12114345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Caro JJ; Getsios D; Caro I; O'Brien JA
    Pharmacoeconomics; 2002; 20(9):593-602. PubMed ID: 12141887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy.
    Rodger MA; Gagné-Rodger C; Howley HE; Carrier M; Coyle D; Wells PS
    Thromb Res; 2003; 112(1-2):13-8. PubMed ID: 15013267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
    Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
    J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
    Huse DM; Cummins G; Taylor DC; Russell MW
    Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shifting from inpatient to outpatient treatment of deep vein thrombosis in a tertiary care center: a cost-minimization analysis.
    Boucher M; Rodger M; Johnson JA; Tierney M
    Pharmacotherapy; 2003 Mar; 23(3):301-9. PubMed ID: 12627927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis.
    Estrada CA; Mansfield CJ; Heudebert GR
    J Gen Intern Med; 2000 Feb; 15(2):108-15. PubMed ID: 10672114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost of managing an episode of relapse in multiple sclerosis in the United States.
    O'Brien JA; Ward AJ; Patrick AR; Caro J
    BMC Health Serv Res; 2003 Sep; 3(1):17. PubMed ID: 12952552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis.
    Gómez-Outes A; Rocha E; Martínez-González J; Kakkar VV
    Pharmacoeconomics; 2006; 24(1):81-92. PubMed ID: 16445305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis.
    Avritscher EB; Cantor SB; Shih YC; Escalante CP; Rivera E; Elting LS
    Support Care Cancer; 2004 Jul; 12(7):531-6. PubMed ID: 14986076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Pharmacomechanical Catheter-Directed Thrombolysis Versus Standard Anticoagulation in Patients With Proximal Deep Vein Thrombosis: Results From the ATTRACT Trial.
    Magnuson EA; Chinnakondepalli K; Vilain K; Kearon C; Julian JA; Kahn SR; Goldhaber SZ; Jaff MR; Kindzelski AL; Herman K; Brady PS; Sharma K; Black CM; Vedantham S; Cohen DJ
    Circ Cardiovasc Qual Outcomes; 2019 Oct; 12(10):e005659. PubMed ID: 31592728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Home treatment of deep vein thrombosis. An out-patient treatment model with once-daily injection of low-molecular-weight heparin (tinzaparin) in 555 patients.
    Lapidus L; Börretzen J; Fahlén M; Thomsen HG; Hasselblom S; Larson L; Nordström H; Stigendal L; Waller L
    Pathophysiol Haemost Thromb; 2002; 32(2):59-66. PubMed ID: 12214150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis.
    Gould MK; Dembitzer AD; Sanders GD; Garber AM
    Ann Intern Med; 1999 May; 130(10):789-99. PubMed ID: 10366368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
    Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
    CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does low-molecular-weight heparin reduce the costs of venous thromboembolism treatment?
    Bossuyt PM; Prins MH
    Haemostasis; 2000; 30 Suppl 2():136-40; discussion 128-9. PubMed ID: 11251358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects.
    Hull RD; Pineo GF; Raskob GE
    Haemostasis; 1998; 28 Suppl 3():8-16. PubMed ID: 10069757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis.
    O'Brien B; Levine M; Willan A; Goeree R; Haley S; Blackhouse G; Gent M
    Arch Intern Med; 1999 Oct; 159(19):2298-304. PubMed ID: 10547169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy.
    Spyropoulos AC; Frost FJ; Hurley JS; Roberts M
    Chest; 2004 May; 125(5):1642-50. PubMed ID: 15136371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective.
    Hull RD; Raskob GE; Rosenbloom D; Pineo GF; Lerner RG; Gafni A; Trowbridge AA; Elliott CG; Green D; Feinglass J
    Arch Intern Med; 1997 Feb; 157(3):289-94. PubMed ID: 9040295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.